2.7 C
New York
Wednesday, February 1, 2023

An Evaluation Of Zymeworks Inc. (NASDAQ: ZYME) Prospects

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Zymeworks Inc. (ZYME) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $1.70, or 17.00%, to $11.70. The Zymeworks Inc. has recorded 53,914 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

ZYME belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $10.00 and fluctuated between $10.68 as its day high and $9.81 as its day low. The current market capitalization of Zymeworks Inc. is $544.00M. A total of 0.94 million shares were traded on the day, compared to an average of 1.52M shares.

In the most recent transaction, EcoR1 Capital, LLC bought 203,000 shares of ZYME for 10.00 per share on Jan 18. After the transaction, the 10% Owner now owns 9,579,973 company shares. In a previous transaction on Jan 17, EcoR1 Capital, LLC bought 440,000 shares at 9.80 per share. ZYME shares that 10% Owner owns now total 9,376,973.

Among the insiders who bought shares, EcoR1 Capital, LLC acquired of 342,100 shares on Jan 13 at a per-share price of $9.81. This resulted in the 10% Owner holding 8,936,973 shares of ZYME after the transaction. In another insider transaction, EcoR1 Capital, LLC bought 106,300 shares at $7.87 per share on Jan 11. Company shares held by the 10% Owner now total 8,594,873.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ZYME in the last 3 months, the mean price target is $12.67 with high estimates of $21.00 and low estimates of $8.00. In terms of 52-week highs and lows, ZYME has a high of $15.02 and a low of $4.11.

As of this writing, ZYME has an earnings estimate of -$0.9 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.74 per share and a lower estimate of -$1.15. The company reported an EPS of -$1.18 in the last quarter, which was 29.30% higher than expectations of -$1.67.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 12 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Hold with a score of 4.27. A total of 8 analysts rated the stock as Buy while 0 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles